Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-09-01
2010-02-02
Fetterolf, Brandon J (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07655771
ABSTRACT:
Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the CYP3A4 and CYP3A7 genes. In particular, polynucleotides of molecular variant CYP3A4 and CYP3A7 genes which, for example, are associated with insufficient metabolization and/or sensitivity of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP3A4 and CYP3A7 proteins are described. In addition, variant CYP3A4 and CYP3A7 proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP3A4 and CYP3A7 genes as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies and inhibitors by the above-described method are provided. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP3A4 or CYP3A7 gene product.
REFERENCES:
patent: 6025131 (2000-02-01), Larossa et al.
patent: 6821724 (2004-11-01), Mittman et al.
patent: 0 759 476 (1997-02-01), None
patent: WO 91/10745 (1991-07-01), None
patent: WO 99/13106 (1999-03-01), None
patent: WO 00/24926 (2000-05-01), None
Westlind et al. (IDS, 1999).
Lichter (IDS, 1999).
Overbeek (1994, “Factors affecting transgenic animal production,” Transgenic animal technology, pp. 96-98).
Wall, 1996 Theriogenology, vol. 45, pp. 57-68.
Houdebine, 1994, J. Biotech. vol. 34, pp. 269-287.
Kappell, 1992, Current Opinions in Biotechnology, vol. 3, pp. 548-553.
Cameron, 1997, Molec. Biol. 7, pp. 253-265.
Niemann, 1997, Transg. Res. 7, pp. 73-75.
Mullins (1993, Hypertension, vol. 22, pp. 630-633).
Mullins (1990, Nature, vol. 344, 541-544).
Hammer (1990, Cell, vol. 63, 1099-1112).
Mullins, 1989, EMBO J., vol. 8, pp. 4065-4072.
Taurog, 1988, Jour. Immunol., vol. 141, pp. 4020-4023.
Mullins (1996, J. Clin. Invest. vol. 98, pp. S37-S40).
Gura (Science, v278, 1997, pp. 1041-1042).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Verma et al. (1997) Nature vol. 389, p. 239-242.
Marshall (1995) Science, vol. 269, Issue 5227, pp. 1050-1055.
Eck et al. (Goodman & Gilman's The Pharmacological Basis of Therapeutics (1996), 9th Edition, Chapter 5, McGraw-Hill, NY).
Juengst (British Medical Journal (2003) vol. 326, pp. 1410-1411).
Rubanyi (Mol. Aspects Med. (2001) 22:113-142).
Hashimoto, H. et al., “Gene Structure of CYP3A4, an Adult-specific Form of Cytochrom P 450 in Human Livers, and its Transcriptional Control,”European Journal of Biochemistry218:585-595 (1993).
Sata, F. et al., “CΥP3A4 Allelic Variants with Amino Acid Substitutions in Exons 7 and 12: Evidence for an Allelic Variant with Altered Catalytic Activity,”Clinical Pharmacology&Therapeutics67:48-56 (2000).
Westlind, A. et al., “Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory Region,”Biochemical and Biophysical Research Communications259:201-205 (1999).
Gellner, K. et al., “Genomic Organization of the Human CYP3A Locus: Identification of a New, Inducible CYP3A Gene Expressed in the Liver, Testes and Prostate,” (Abstract) NCBI Protein and Nucleotide Databases, Nov. 15, 2000, AC= AAG32290. Cytochrome P450 Polypeptide 4; CYP3A4.Homo sapiens(Human).
Beaune et al., “Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase”,Proceedings of the National Academy of Sciences of the United States of America, 83:8064-8068 (1986).
Eiselt et al., “Identification and functional characterization of eight CYP3A4 protein variants”,Pharmacogenetics, 11:447-458 (2001).
Hashimoto et al., “Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control”,European journal of biochemistry / FEBS, 218:585-595 (1993).
Wang et al., “Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms”,Drug Metabolism and Disposition, 27(2):167-172 (1999).
Westlind et al., “Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5'-Upstream Regulatory Region”,Biochemical and Biophysical Research Communications, 259:201-205 (1999).
EMBL-Bank Accession No. A1638117, “ts50e10.xl NCI—CGAP—Utl Homo sapiens cDNA clone Image:2232042 3' similar to gb:J04182 Lysosome-Associated Membrane Glycoprotein 1 Precursor (Human);, mRNA sequence.”.
Eiselt Regina
Wojnowski Leszek
Fetterolf Brandon J
PGx Health, LLC
LandOfFree
Polymorphisms in the human cyp3a4 and cyp3a7 genes and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphisms in the human cyp3a4 and cyp3a7 genes and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphisms in the human cyp3a4 and cyp3a7 genes and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4229594